Abbott Labs rises on hepatitis C drug data (Update)

October 15, 2012

Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease.

Patients who took a three-drug regimen and the drugs Ritonavir and ribavirin had undetectable virus levels after 12 weeks of treatment. The North Chicago, Illinois, company says it observed a 93 percent cure rate in a group of patients who were not helped by other treatments.

Patients in the trial had genotype 1 hepatitis C, which is the most common type in the Western world and the hardest to treat. The regimen did not include interferon, a standard component of hepatitis C therapy that causes flu-like side effects that can last for months. The study included 77 patients who hadn't been treated before and 41 patients who were not helped by other treatments.

Abbott shares rose $2.63, or 3.8 percent, to $71.90 in afternoon trading. The stock has been trading around all-time highs and peaked at $71.99 earlier in the session.

Shares of Bristol-Myers Squibb Co. also traded higher on promising data for a hepatitis C regimen. The company said 94 percent of patients who took a combination of three experimental drugs, daclatasvir, asunaprevir, and BMS-791325, were cured in a 12-week study. Those patients did not take interferon or ribavirin.

Shares of Bristol-Myers Squibb rose 88 cents, or 2.7 percent, to $33.97 in afternoon trading.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the U.S. Analysts say the market for treatments is potentially lucrative for drugmakers. More people are expected to be diagnosed with the tough-to-treat disease as the baby boomer generation ages.

After a two-decade drought, two new hepatitis C drugs were approved last year: Merck & Co.'s Victrelis and Incivek from Vertex Pharmaceuticals Inc. and Johnson & Johnson. Both significantly improve the cure rate over what has long been the standard of care, a mix of injections and pills with nasty side effects that takes several months and still doesn't cure many patients.

Citi Investment Research analyst Yaron Werber said the study results were strong, particularly in newly diagnosed patients. However he said the regimen is complicated because it includes five different types of pills, and Ritonavir can cause serious side effects when taken with some other medications. Werber said he believes a regimen being studied by Gilead Sciences Inc. could produce similar cure rates with fewer pills.

Gilead's approach uses two experimental pills, including its drug candidate sofosbuvir, as well as ribavirin.

Explore further: Shorter treatment with hepatitis C drug combination may be more beneficial, study shows

shares

Related Stories

Shorter treatment with hepatitis C drug combination may be more beneficial, study shows

September 14, 2011
University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication—a telaprevir-based ...

Combination of oral drugs suppresses common type of hepatitis C

January 19, 2012
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

Recommended for you

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

Introduction is different, but top medications for opioid addiction equally effective

November 14, 2017
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the ...

Drugstore pain pills as effective as opioids in ER patients

November 7, 2017
Emergency rooms are where many patients are first introduced to powerful opioid painkillers, but what if doctors offered over-the-counter pills instead? A new study tested that approach on patients with broken bones and sprains ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.